Clinical trial finds that oral drug MK-0616 substantially reduces ‘bad’ cholesterol
MK-016 could offer another potential option to achieve guideline-recommended LDL-C levels resulting in reduction of cardiovascular risk.
Read MoreMK-016 could offer another potential option to achieve guideline-recommended LDL-C levels resulting in reduction of cardiovascular risk.
Read More